Yıl: 2021 Cilt: 32 Sayı: 1 Sayfa Aralığı: 40 - 46 Metin Dili: İngilizce DOI: 10.14744/scie.2020.19970 İndeks Tarihi: 17-06-2021

Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer

Öz:
Objective: Fractalkine is a chemotactic agent that shows both tumorogenic and anti-tumorogenicactivity in some cancer types. In this study, we investigated the role of fractalkinein the diagnosis, progression and recurrence of primer non-muscle-invasive bladder cancer(NMIBC) and compared it with the healthy population.Methods: Overall, 84 people that consisted of 44 cases with primary NMIBC and 40 healthycontrols enrolled for this study. Blood and urine samples were collected and fractalkine levelswere measured by the ELISA method. Urinary creatinine levels were calculated and urinaryfractalkine levels were optimized. Demographic data, tumor stage (Ta, T1), grade (low andhigh), number of tumors, tumor size, recurrence and progression status of patients were recorded.NMP22 test was performed on the patient group and urine cytology was sent fromthe patients. Fractalkine levels and subgroup analyses were compared between two groups.Results: The mean age of patients was 63.9±11.1 and 62.3±9.6 in the control group. Themean urinary fractalkine level was7.8±0.9 ng/ml in the study group and 7.7±0.6 ng/ml inthe control group; there was no statistically significant difference between the two groups(p=0.426). Mean urinary fractalkine/creatinine level was similar between the study groupand control group (16.0±32.2 ng/mgCr and 11.1±7.0 ng/mgCr, respectively, p=0.781). Meanserum fractalkine level was 2.9±1.2 ng/ml in the study group and 2.9±0.7 ng/ml in the controlgroup; there was not a statistically significant difference (p=0.183). Also, we could notfind any relation of fractalkine levels with tumor size, number, recurrence and progression.NMP 22 test was positive in half of the study group and Fractalkine levels were higher inthe patients that NMP22 tests were negative that was statistically significantly. Cytology waspositive for 45.5% of patients, but there was not any statistical correlation between fractalkinelevels and cytology.Conclusion: In this study, we did not find a significant difference concerning serum andurinary fractalkine level between the two groups. These findings do not support the use offractalkine as a biomarker for bladder cancer diagnosis and follow-up.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Fleshner NE, Herr HW, Stewart AK, Murphy GP, C Mettlin, Mwnck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1996;78:1505–13.
  • 2. Goodison S, Rosser CJ, Urquidi V Bladder Cancer Detection and Monitoring: Assessment of Urine- and Blood-Based Marker Tests. Mol Diagn Ther 2013;17:71–84.
  • 3. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-based assays for the detection of bladder cancer. Biomark Med 2009;3:265.
  • 4. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35–63.
  • 5. Liu W, Jiang L, Bian C, Liang Y, Xing R, Yishakea M, et al. Role of CX3CL1 in Diseases. Arch Immunol Ther Exp (Warsz) 2016;64:371−83.
  • 6. Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N. Fractalkine- CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 2007;95:241–9.
  • 7. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, et al Expression of chemo ine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006;17:945–51.
  • 8. Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89:1–7.
  • 9. Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T, et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006;36:1019–27.
  • 10. Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35:1371–80.
  • 11. Robinson LA, Nataraj C, Thomas DW, Cosby JM, Griffiths R, Bautch VL, et al. The chemokine CX3CL1 regulates NK cell activity in vivo. Cell Immunol 2003;225:122–30.
  • 12. Jamieson WL, Shimizu S, D’Ambrosio JA, Meucci O, Fatatis A. CX- 3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008;68:1715–22.
  • 13. Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008;14:7790–7.
  • 14. Jamshidian H, Kor K, Djalali M. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J 2008;5:243–7.
  • 15. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810–6.
  • 16. Doğan C, Pelit ES, Yıldırım A, Zemheri IE, Çanakcı C, Başok EK, et al. Yüzeyel mesane tümörlü hastaların tanı ve takibinde NMP22 testinin değerliliği. Turkish Journal of Urology 2013;39:137–42.
  • 17. Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165:1462–7.
  • 18. Murphy WM, Soloway MS, Jukkola AF, Crabtree WN, Ford KS. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer 1984;53:1555–65.
  • 19. Têtu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;22 Suppl 2: S53–9.
  • 20. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al; FinnBladder Group. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284–9.
  • 21. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975–82.
  • 22. Kumar A, Kumar R, Gupta NP. Comparision of NMP22 Bladder- Chek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172–5.
  • 23. Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study. Can J Urol 2012;19:6345–50.
  • 24. David P. Wood Urothelial Tumors of The Bladder. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders; 2012. p. 2309–34.
  • 25. Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014;120:408–14.
  • 26. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 2013;64:456–64
  • 27. Qin Q, Xu X, Wang X, Zheng XY. Obesity and Risk of Bladder Cancer: A Meta-analysis of Cohort Studies Asian Pac J Cancer Prev 2013;14:3117–21.
  • 28. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 2013;190:480–6.
  • 29. Koebnick C, Michaud D, Moore SC, Park Y, Hollenbeck A, Ballard- Barbash R, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2008;17:1214–21.
APA CANAKCI C, Yildirim A, ARIKAN Ö, Basok B, Atis G, gurbuz c, Ozkanli S, ISMAN F, Caskurlu T (2021). Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. , 40 - 46. 10.14744/scie.2020.19970
Chicago CANAKCI Cengiz,Yildirim Asif,ARIKAN Özgür,Basok Banu Isbılen,Atis Gokhan,gurbuz cenk,Ozkanli Seyma,ISMAN FERRUH KEMAL,Caskurlu Turhan Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. (2021): 40 - 46. 10.14744/scie.2020.19970
MLA CANAKCI Cengiz,Yildirim Asif,ARIKAN Özgür,Basok Banu Isbılen,Atis Gokhan,gurbuz cenk,Ozkanli Seyma,ISMAN FERRUH KEMAL,Caskurlu Turhan Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. , 2021, ss.40 - 46. 10.14744/scie.2020.19970
AMA CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. . 2021; 40 - 46. 10.14744/scie.2020.19970
Vancouver CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. . 2021; 40 - 46. 10.14744/scie.2020.19970
IEEE CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T "Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer." , ss.40 - 46, 2021. 10.14744/scie.2020.19970
ISNAD CANAKCI, Cengiz vd. "Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer". (2021), 40-46. https://doi.org/10.14744/scie.2020.19970
APA CANAKCI C, Yildirim A, ARIKAN Ö, Basok B, Atis G, gurbuz c, Ozkanli S, ISMAN F, Caskurlu T (2021). Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. Southern Clinics of Istanbul Eurasia, 32(1), 40 - 46. 10.14744/scie.2020.19970
Chicago CANAKCI Cengiz,Yildirim Asif,ARIKAN Özgür,Basok Banu Isbılen,Atis Gokhan,gurbuz cenk,Ozkanli Seyma,ISMAN FERRUH KEMAL,Caskurlu Turhan Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. Southern Clinics of Istanbul Eurasia 32, no.1 (2021): 40 - 46. 10.14744/scie.2020.19970
MLA CANAKCI Cengiz,Yildirim Asif,ARIKAN Özgür,Basok Banu Isbılen,Atis Gokhan,gurbuz cenk,Ozkanli Seyma,ISMAN FERRUH KEMAL,Caskurlu Turhan Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. Southern Clinics of Istanbul Eurasia, vol.32, no.1, 2021, ss.40 - 46. 10.14744/scie.2020.19970
AMA CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. Southern Clinics of Istanbul Eurasia. 2021; 32(1): 40 - 46. 10.14744/scie.2020.19970
Vancouver CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer. Southern Clinics of Istanbul Eurasia. 2021; 32(1): 40 - 46. 10.14744/scie.2020.19970
IEEE CANAKCI C,Yildirim A,ARIKAN Ö,Basok B,Atis G,gurbuz c,Ozkanli S,ISMAN F,Caskurlu T "Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer." Southern Clinics of Istanbul Eurasia, 32, ss.40 - 46, 2021. 10.14744/scie.2020.19970
ISNAD CANAKCI, Cengiz vd. "Clinical Importance of Serum and Urinary Fractalkine Level in Primary Non-Muscle Invasive Bladder Cancer". Southern Clinics of Istanbul Eurasia 32/1 (2021), 40-46. https://doi.org/10.14744/scie.2020.19970